Perrigo to Divest Infant Formula, E-Commerce Reaches 22% of U.S. Volume

What happened

Perrigo has agreed to divest its infant formula business, a segment that has faced distribution losses and regulatory challenges, marking a major step in the company's ongoing portfolio simplification under the Three-S plan. The move follows a strategic review and likely aims to reduce complexity, improve balance-sheet flexibility, and sharpen focus on higher-margin OTC self-care brands such as Opill and European franchises. Separately, management disclosed that U.S. e-commerce now represents 22% of total U.S. volume, up from a lower base, reflecting a structural shift in how consumers purchase store-brand OTC products. While the e-commerce channel offers growth and convenience, it also introduces new competitive dynamics with large online retailers and potential margin pressure from pricing transparency and logistics costs. Overall, these developments are consistent with the company's stated strategy to stabilize, streamline, and strengthen its core self-care platform, but the financial impact depends on divestiture terms and execution of cost-saving programs.

Implication

Near term, the infant formula divestiture should remove a persistent drag on sales and earnings, and if proceeds are used to pay down debt, it could improve Perrigo's stretched balance sheet, where net debt/EBITDA stands near 7x. However, the business being sold is likely low-margin and capital-intensive, so the financial benefit may be limited unless the price exceeds book value and avoids significant impairment charges. The rise in e-commerce to 22% of U.S. volume indicates a durable channel shift that Perrigo must manage carefully, as online platforms like Amazon can exert pricing power and erode the traditional retailer relationships that underpin Perrigo's private-label advantage. Long-term investors should track whether e-commerce sales are accretive to margins and whether store-brand share is maintained online versus branded competitors. The core thesis of a deeply undervalued self-care company with cost savings and deleveraging potential remains intact but still requires evidence of improved profitability and lower leverage before it can be upgraded from a potential buy to a more confident buy.

Thesis delta

The master report had a thesis of potential buy based on distressed valuation and execution of cost programs, with infant formula divestiture listed as a watch item. The actual agreement to divest infant formula is a positive catalyst that aligns with management's focus and could accelerate deleveraging, but it does not eliminate the primary risks of high leverage and the unresolved Irish tax dispute. The e-commerce data point adds a new dimension to monitor, as channel mix may affect future margins and retailer bargaining power, potentially reinforcing the need for caution on the pace of recovery.